KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies

Oncotarget

Volumn 7, Issue 7, 2016, Pages 8373-8388

  Pan, Wei ^a,b   Yang, Yan ^a   Zhu, Hongcheng ^a   Zhang, Youcheng ^c   Zhou, Rongping ^c   Sun, Xinchen ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

^c THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

EGFR TKI; KRAS mutation; Meta analysis; Non small cell lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; DATA BASE; DISEASE FREE SURVIVAL; DRUG RESPONSE; GENE MUTATION; HUMAN; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PUBLICATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; META ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE;

EID: 84958818903     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7080     Document Type: Article

References (66)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90. doi: 10.3322/caac.20107.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2014; 62:220-41. doi: 10.3322/caac.21149.
3. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21:2237-46. doi: 10.1200/JCO.2003.10.038.
4. Rodenhuis S and Slebos RJ. The ras oncogenes in human lung cancer. Am Rev Respir Dis. 1990; 142:S27-30. doi: 10.1164/ajrccm/142.6_Pt_2.S27.
5. Roberts PJ and Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26:3291-310. doi: 10.1038/sj.onc.1210422.
6. Karachaliou N, Mayo C, Costa C and Magrí I. KRAS mutations in lung cancer. Clin Lung Cancer. 2013; 14:205-14. doi: 10.1016/j.cllc.2012.09.007.
7. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N and Mooi WJ. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990; 323:561-5. doi: 10.1056/NEJM199008303230902.
8. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23:5900-9. doi: 10.1200/JCO.2005.02.857.
9. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clinical Cancer Research. 2007; 13:2890-6. doi: 10.1158/1078-0432.CCR-06-3043.
10. Kim HR, Shim HS, Chung J-H, Lee YJ, Hong YK, Rha SY, Kim SH, Ha S-J, Kim SK, Chung KY, Soo R, Kim JH and Cho BC. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2011; 118:729-39. doi: 10.1002/cncr.26311.
11. Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V and Crinò L. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer. 2012; 78:81-6. doi: 10.1016/j.lungcan.2012.06.005.
12. Camps C, Jantus-Lewintre E, Cabrera A, Blasco A, Sanmartín E, Gallach S, Caballero C, del Pozo N, Rosell R, Guijarro R and Sirera R. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011; 72:365-9. doi: 10.1016/j.lungcan.2010.09.005.
13. Nygaard AD, Garm Spindler K-L, Pallisgaard N, Andersen RF and Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013; 79:312-7. doi: 10.1016/j.lungcan.2012.11.016.
14. Mellema WW, Dingemans A-MC, Thunnissen E, Snijders PJF, Derks J, Heideman DAM, Van Suylen R and Smit EF. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. J Thorac Oncol. 2013; 8:1190-5. doi: 10.1097/JTO.0b013e318298764e.
15. Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, et al. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014; 15:86-92. doi: 10.1016/j.cllc.2013.08.002.
16. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M and Pao W. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3:111-6. doi: 10.1097/JTO.0b013e318160c607.
17. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz J-C, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26:4268-75. doi: 10.1200/JCO.2007.14.8924.
18. Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F and Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res. 2009; 29:2767-73.
19. Jackman DM, Miller VA, Cioffredi L-A, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV and Johnson BE. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clin Cancer Res. 2009; 15:5267-73. doi: 10.1158/1078-0432.CCR-09-0888.
20. Liu H-P, Isaac Wu H-D, Chang JW-C, Wu Y-C, Yang H-Y, Chen Y-T, Hsieh W-Y, Chen Y-T, Chen Y-R and Huang S-F. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol. 2010; 5:1175-84. doi: 10.1097/JTO.0b013e3181e2f4d6.
21. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6:707-15. 10.1097/JTO.0b013e31820a3a6b.
22. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K and Cappuzzo F. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:4113-20. doi: 10.1200/JCO.2010.31.8162.
23. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M and Riely GJ. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2012; 119:356-62. doi: 10.1002/cncr.27730.
24. Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L and Puma F. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. American Journal of Clinical Oncology. 2014; 37:343-9. doi:10.1097/COC.0b013e31827a7e7a.
25. Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon J-P, Graziano S, Douillard J-Y, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le TeuffG, Pirker R, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013; 31:2173-81. doi: 10.1200/JCO.2012.48.1390.
26. Kerner GSMA, Schuuring E, Sietsma J, Hiltermann TJN, Pieterman RM, de Leede GPJ, van Putten JWG, Liesker J, Renkema TEJ, van Hengel P, Platteel I, Timens W and Groen HJM. Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome. PLoS ONE. 2013; 8:e70346. doi: 10.1371/journal.pone.0070346.
27. Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon JP and Soria JC. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? Lung Cancer. 2014; 83:383-8. doi: 10.1016/j.lungcan.2013.12.013
28. Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014; 50:1819-28. doi: 10.1016/j.ejca.2014.04.001.
29. Kim YT, Kim T-Y, Lee DS, Park SJ, Park J-Y, Seo S-J, Choi H-S, Kang HJ, Hahn S, Kang CH, Sung SW and Kim JH. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2008; 59:111-8. doi: 10.1016/j.lungcan.2007.08.008.
30. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, Tajiri M, Rino Y, Kitamura H and Masuda M. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009; 65:355-62. doi: 10.1016/j.lungcan.2008.11.020.
31. Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine M-P, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol. 2012; 7:1490-502. doi: 10.1097/JTO.0b013e318265b2b5.
32. Guan J-L, Zhong W-Z, An S-J, Yang J-J, Su J, Chen Z-H, Yan H-H, Chen Z-Y, Huang Z-M, Zhang X-C, Nie Q and Wu Y-L. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol. 2013; 20:1381-8. doi: 10.1245/s10434-012-2754-z.
33. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H and Kinoshita I. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380-8. doi: 10.1056/NEJMoa0909530.
34. Sun J-M, Hwang DW, Ahn JS, Ahn M-J and Park K. Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS ONE. 2013; 8:e64816. doi: 10.1371/journal.pone.0064816.
35. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. Plos Med. 2005; 2:e17. doi: 10.1371/journal.pmed.0020017.
36. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF and Ladanyi M. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18:6169-77. doi: 10.4999/uhod.13083.
37. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, Bauer TT and Mairinger T. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013; 3:e002560-0. doi: 10.1136/bmjopen-2013-002560.
38. Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR and Betticher DC. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007; 254:265-73. doi: 10.1016/j.canlet.2007.03.008.
39. Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009; 4:22-9. doi: 10.1097/JTO.0b013e3181914111.
40. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia. 2009; 11:1084-92.
41. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F and Favaretto A. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res. 2010; 30:5121-8.
42. Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, et al. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 2012; 69:1289-99. doi: 10.1007/s00280-012-1829-7.
43. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK and Hainaut P. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal. 2012; 40:177-84. doi: 10.1183/09031936.00097311.
44. Gao J, Chen J-Q, Zhang L and Liang Z-Y. Relationship between EGFR and KRAS mutations and prognoisis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scropion amplification refractory mutation system. Zhonghua Bing Li Xue Za Zhi. 2012; 41:652-6. doi: 10.3760/cma.j.issn.0529-5807.2012.10.002.
45. Kim ST, Sung JS, Jo UH, Park KH, Shin SW and Kim YH. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol. 2013; 30:328-10. doi: 10.1007/s12032-012-0328-3
46. Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z and Minarik M. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res. 2013; 33:1705-11.
47. Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EEF, Bernardo LA, Dias-Santagata D, Iafrate AJ and Lanuti M. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014; 9:1363-9. doi: 10.1097/JTO.0000000000000266.
48. Nadal E, Beer DG, Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2015; 10:e9-10. doi: 10.1097/JTO.0000000000000438.
49. Campos-Parra AD, Zuloaga C, Manríquez MEV, Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A and Arrieta O. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. American Journal of Clinical Oncology. 2015; 38:33-40. doi: 10.1097/COC.0b013e318287bb23.
50. Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T, et al. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer. Cancer Sci. 2015; 106:1402-07. doi: 10.1111/cas.12740.
51. Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, et al. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015; 26:2079-84. doi: 10.1093/annonc/mdv318.
52. Riely GJ, Marks J and Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 6:201-5. doi: 10.1513/pats.200809-107LC.
53. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62:6997-7000.
54. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27:2091-6. doi: 10.1200/JCO.2009.21.9170.
55. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert A-P, Noel S, Lafitte J-J and Sculier J-P. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2004; 92:131-9. doi: 10.1038/sj.bjc.6602258.
56. Mao C, Qiu L-X, Liao R-Y, Du F-B, Ding H, Yang W-C, Li J and Chen Q. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer. 2010; 69:272-8. doi: 10.1016/j.lungcan.2009.11.020.
57. Ying M, Zhu X, Chen K, Sha Z and Chen L. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. J Cancer Res Clin Oncol. 2015; 141:1427-39. doi: 10.1007/s00432-015-1910-9.
58. Zhang Y, Fang W, Yan Y, Wang M, Kang S, Sheng J, Zhan J, Chen N, Hong S, Yang Y, Ma Y, He D, Qin T, et al. The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis. Med Oncol. 2015; 32:61. doi: 10.1007/s12032-015-0489-y.
59. Fiala O, Pesek M, Finek J, Benesova L, Belsanova B and Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013; 206:26-31. doi: 10.1016/j.cancergen.2012.12.003.
60. Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, Ren-Heidenreich L, Shi B, Ren H, Chu X, Kang J, Wang W, Xu J, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014; 110:2812-20. doi: 10.1038/bjc.2014.210.
61. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A and Broggini M. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011; 22:235-7. doi: 10.1093/annonc/mdq680.
62. Dingemans A-MC, Mellema WW, Groen HJM, van Wijk A, Burgers SA, Kunst PWA, Thunnissen E, Heideman DAM and Smit EF. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res. 2013; 19:743-51. doi: 10.1158/1078-0432.CCR-12-1779.
63. Metro G, Chiari R, Baldi A, De Angelis V, Minotti V and Crinò L. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. Future Oncol. 2013; 9:167-77. doi:10.2217/fon.12.198.
64. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, et al. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014; 5:8937-46. doi: 10.18632/oncotarget.2339.
65. Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, et al. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget. 2014; 5:7635-50. doi: 10.18632/oncotarget.2339.
66. Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. doi:10.1186/1745-6215-8-16.